BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Maruho readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Maruho's drugs run\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07074977-1524@assetmemo.bio
DTSTAMP:20261120T230535Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nemluvio (nemolizumab): Phase 2 readout est. (NCT07074977)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2.\nStudy: Proof of Concept Stud
 y to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults
  With Chronic Pruritus of Unknown Origin (CPUO)\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 emolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07074977
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06804811-11030@assetmemo.bio
DTSTAMP:20261120T230535Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ruxolitinib (Opzelura): Phase 3 readout est. (NCT06804811)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 3\, Vitiligo.\nStudy: A Study to
  Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to <
  12 Years Old) With Nonsegmental Vitiligo\nEstimated primary completion: 3
 0 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolit
 inib-opzelura#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06804811
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616128-1364@assetmemo.bio
DTSTAMP:20261120T230535Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:EVO756: Phase 2 readout est. (NCT07616128)
DESCRIPTION:EVO756\, phase 2\, Migraine.\nStudy: Study of EVO756 in Adults 
 With Migraine\nEstimated primary completion: October 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/evo756#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07616128
URL:https://assetmemo.bio/drug/evo756#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762833-1524@assetmemo.bio
DTSTAMP:20261120T230535Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Nemluvio (nemolizumab): Phase 3 readout est. (NCT07762833)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 3\, Atopic Dermatitis.\nStudy: R
 andomized\, Double-blind\, Placebo-controlled Study of Nemolizumab in Chin
 ese Subjects With Moderate-to-severe Atopic Dermatitis\nEstimated primary 
 completion: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07762833
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047690-1524@assetmemo.bio
DTSTAMP:20261120T230535Z
DTSTART;VALUE=DATE:20280528
DTEND;VALUE=DATE:20280529
SUMMARY:Nemluvio (nemolizumab): Phase 2 readout est. (NCT07047690)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2.\nStudy: A Study of Nemolizuma
 b for the Treatment of Adults With Systemic Sclerosis\nEstimated primary c
 ompletion: 28 May 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07047690
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548360-11030@assetmemo.bio
DTSTAMP:20261120T230535Z
DTSTART;VALUE=DATE:20280605
DTEND;VALUE=DATE:20280606
SUMMARY:Ruxolitinib (Opzelura): Phase 3 readout est. (NCT06548360)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 3\, Vitiligo.\nStudy: A Study to
  Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Partic
 ipants With Nonsegmental Vitiligo\nEstimated primary completion: 5 June 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-opzel
 ura#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06548360
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07660835-1524@assetmemo.bio
DTSTAMP:20261120T230535Z
DTSTART;VALUE=DATE:20280715
DTEND;VALUE=DATE:20280716
SUMMARY:Nemluvio (nemolizumab): Phase 2 readout est. (NCT07660835)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2\, Atopic Dermatitis.\nStudy: P
 harmacokinetics\, Safety and Efficacy of Nemolizumab in Participants Aged 
 6 to 23 Months With Moderate-to Severe Atopic Dermatitis\nEstimated primar
 y completion: 15 July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07660835
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
